Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN046 plus chemotherapy in advanced squamous NSCLC
NCT04474119Phase 3Unknown
- Sponsor
- Alphamab Oncology
- Start
- Sep 2020
- Primary completion
- Aug 2022
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of erfonrilimab in squamous cell carcinoma of the lung (SCCL), sponsored by Alphamab Oncology. Status: unknown.
02
Drugs
erfonrilimab
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT04474119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04474119.